Lactation Affecting Patents (Class 514/4.7)
-
Patent number: 9561261Abstract: The present invention relates to the use of one or more Relaxin proteins in methods for diagnoses and treatment of multiple sclerosis. The invention also provides compositions for use in diagnosing or treating multiple sclerosis as well as the methods themselves. Kits for carrying out the methods are also described.Type: GrantFiled: June 25, 2012Date of Patent: February 7, 2017Assignee: BVBIOMED LTD.Inventors: Roy Garvin, Alasdair Burns
-
Patent number: 9144556Abstract: It is an object of the present invention to provide a composition containing lactoferrin and another component and having a prominent effect of promoting visceral lipolysis. That is, the present invention is a composition for promoting the lipolysis; a food product, a feedstuff or a pharmaceutical product including (A) lactoferrin and (B) one or more ingredients selected from the group consisting of a Durvillaea extract, raspberry ketone, an artichoke leaf extract, a rosemary extract, isoflavone, a grape seed extract, a pine bark extract, a Coleus forskohlii extract, and a cacao extract. Also provided is a method of giving the effect of promoting the lipolysis to the food product or the feedstuff by adding the component (A) and the component (B) for promoting the lipolysis to the food product or the feedstuff.Type: GrantFiled: January 20, 2012Date of Patent: September 29, 2015Assignee: LION CORPORATIONInventors: Noriyuki Suzuki, Michiaki Murakoshi, Tomoji Ono, Chikako Fujisaki
-
Publication number: 20150093400Abstract: The present invention provides novel short peptides that are highly effective in inducing involution in a mammary gland of a lactating mammal and cessation of milk production by the gland. The invention further provides pharmaceutical composition comprising the peptides and methods of use thereof including for treating microbial infection in a mammary gland.Type: ApplicationFiled: March 8, 2013Publication date: April 2, 2015Inventors: Jose Mario Iscovich, Javier Iscovich
-
Publication number: 20140274886Abstract: In a ruminant feed, rumen undegraded protein (“RUP”), which is protein orally ingested and passed through the rumen in an undegraded or undigested state, is determined through analysis of feed components in the feed and is used to modify the feed formulation to control a level of RUP exiting the rumen of the ruminant. Additionally the RUP and rumen undegraded neutral detergent fiber (“RUNDF”) content of selected feed components may be received based on an analysis of the feed components and the feed ration may be formulated accordingly. The RUP content may be determined by comparing analysis results with a calibration curve of previously analyzed feed components.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Inventor: David C. Weakley
-
Publication number: 20140221277Abstract: Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also provided are methods of using certain synthetic tetrapeptide amides which are peripherally selective kappa opioid receptor agonists to elevate or stabilize serum prolactin levels.Type: ApplicationFiled: November 22, 2013Publication date: August 7, 2014Applicant: CARA THERAPEUTICS, INC.Inventors: Frederique Menzaghi, Michael E. Lewis, Derek T. Chalmers
-
Publication number: 20140171360Abstract: A nutritional supplement, a method for increasing the bacterial mass in the rumen of a ruminant and a nutritional preparation and corresponding uses. A nutritional supplement including proteins with a degree of hydrolysis above 28% and/or which have more than 23 mg ?-amino nitrogen per gram of protein and/or have more than 10% of free amino acids. The hydrolyzed proteins are animal proteins, preferably hemoglobin. The supplement is supplied orally, included in a nutritional preparation, in liquid, concentrated or dehydrated form.Type: ApplicationFiled: July 6, 2012Publication date: June 19, 2014Applicant: APC EUROPE S.A.Inventors: Francisco Javier Polo Pozo, Carmen Rodriguez Canel, Alejandro Bach Ariza, Anna Aris Giralt
-
Patent number: 8680050Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in administration to animals.Type: GrantFiled: August 2, 2010Date of Patent: March 25, 2014Assignee: Amunix Operating Inc.Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-Wei Wang, Nathan Geething, Jeffrey L. Cleland
-
Publication number: 20130172241Abstract: Composition and method for processing prolamin-containing feed source into a low-vitreous gelatinous feedstuff. The feedstuff is fed to ruminant animals for the purpose of potentiating either milk production and/or conception. The feed source can be corn and the ruminant animal can be a bovine, and might be a cow. The method includes processing, by extrusion, a prolamin-containing feed source having a starch-protein matrix within which the included protein is composed of at least 3% percent prolamin. This processing produces a hydrophilic gelatinous feedstuff that has starch and protein content. The hydrophilic low-vitreous gelatinous feedstuff is fed to a ruminant animal. A rumen-retained portion of the fed feedstuff is retained within the rumen of the animal for at least a twenty-four hour period, and during the first twenty-four hours of that period, at least seventy-five percent of the starch content of the rumen-retained portion of the fed feedstuff is digested.Type: ApplicationFiled: December 31, 2012Publication date: July 4, 2013Inventors: Mark D. HOLT, Matthew R. GARNER
-
Publication number: 20130040876Abstract: Disclosed herein are compositions and methods useful for the treatment of cancer, such as breast cancer. In some embodiments, the methods and compositions include human prolactin, or human prolactin in conjunction with a cytotoxic agent. In other embodiments, the methods and compositions include one or more of human prolactin, growth hormone and placental lactogen, or one or more of human prolactin, growth hormone and placental lactogen in conjunction with a cytotoxic agent. In some embodiments, the cytotoxic agent comprises a chemotherapeutic agent.Type: ApplicationFiled: February 2, 2011Publication date: February 14, 2013Inventors: Wen Yuan Chen, Eric H. Lee
-
Publication number: 20130012431Abstract: Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also provided are methods of using certain synthetic tetrapeptide amides which are peripherally selective kappa opioid receptor agonists to elevate or stabilize serum prolactin levels.Type: ApplicationFiled: July 6, 2012Publication date: January 10, 2013Applicant: CARA THERAPEUTICS, INC.Inventors: Frederique Menzaghi, Michael E. Lewis, Derek T. Chalmers
-
Publication number: 20120214733Abstract: The present invention relates to oxytocin receptor agonist compounds, pharmaceutical compositions comprising the same, use of such compounds for the manufacture of a medicament for treatment of inter alia, abdominal pain, irritable bowel syndrome (IBS), autism, erectile dysfunction, female sexual dysfunction, labor induction and maintenance, lactation induction and maintenance, postpartum hemorrhage, Post Traumatic Stress Disorder (PTSD), pain, anxiety and other conditions, as well as to methods for the treatment of such conditions, wherein such compounds are administered.Type: ApplicationFiled: September 21, 2010Publication date: August 23, 2012Applicant: FERRING INTERNATIONAL CENTER S.A.Inventors: Kazimierz Wisniewski, Claudio Daniel Schteingart, Sudarkodi Alagarsamy, Robert Galyean
-
Patent number: 8217000Abstract: Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also provided are methods of using certain synthetic tetrapeptide amides which are peripherally selective kappa opioid receptor agonists to elevate or stabilize serum prolactin levels.Type: GrantFiled: May 22, 2007Date of Patent: July 10, 2012Assignee: Cara Therapeutics, Inc.Inventors: Frederique Menzaghi, Michael E. Lewis, Derek T. Chalmers
-
Publication number: 20110212886Abstract: The present invention relates to peptides derived from casein and their use in the management of lactating animals, particularly to methods for decreasing the length of the dry period of a lactating livestock animal, for increasing its milk yield and milk hygiene after parturition and for improving the livestock welfare. The present invention further relates to pharmaceutical compositions comprising peptides derived from casein in the form of a sterile solution, which compositions are clear and substantially devoid of micelles.Type: ApplicationFiled: May 13, 2011Publication date: September 1, 2011Applicants: MILEUTIS LTD., State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research OrganizationInventors: Jose Mario Iscovich, Nissim Silanikove, Javier Iscovich
-
Publication number: 20110183886Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.Type: ApplicationFiled: March 29, 2011Publication date: July 28, 2011Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
-
Publication number: 20110172146Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in administration to animals.Type: ApplicationFiled: August 2, 2010Publication date: July 14, 2011Applicant: Amunix Operating, Inc.Inventors: VOLKER SCHELLENBERGER, Joshua Silverman, Willem P. Stemmer, Chia-Wei Wang, Nathan Geething
-
Publication number: 20110044905Abstract: The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia compromised lactation conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.Type: ApplicationFiled: March 30, 2009Publication date: February 24, 2011Applicant: Ferring B.V.Inventors: Sudar Alagarsamy, Robert Galyean, Kazimierz Wisniewski, Claudio Schteingart